Annual data

Objective

Develop a global standard for continued provision of treatment following the end of a trial programme and complete roll out by end year.

Targets

Disclosure of clinical trials in line with AstraZeneca policy requirements.

Continued programme of risk based assessments in countries where AstraZeneca conducts trials as well as for new countries with the potential of being selected for future study placement.

Disclosure of clinical trials in line with AstraZeneca policy requirements.

Measurement of our external reputation relating to R&D ethics. 

Disclosure of clinical trials in line with AstraZeneca policy requirements: by the end of 2011 we had registered over 1,370 trials and posted the results of more than 1,150 on public websites.

Global standard rolled out for continued provision of treatment following the end of a trial programme.

88% score for R&D ethics in Dow Jones Index (no change from 2010).

Our global governance process for determining where we place clinical trials provides the framework for ensuring a consistent approach worldwide.

Objectives

To be recognised globally as adopting and promoting methodologies in the conduct of clinical trials that ensure patients are treated ethically and safely.

To be recognised as an industry leader in the publication and sharing of clinical trial information.

Targets

Review (across a selected range of countries with differing cultures and medical practices) of best practice use of new communication tools and media to better communicate with and protect the interests of patients, in particular those with limited education, income and healthcare coverage.

Design a package of tools to employ the best practice identified from the review and ensure availability for use AstraZeneca employees and AstraZeneca appointed third parties engaged in the conduct of clinical trials.

Clinical trials information published in line with our disclosure policy.

Conduct a review of all items of information that constitute any part of the drug design and development process, in order to share as much information publicly as possible.

Improvement in our external reputation relating to R&D ethics in commentaries made by Dow Jones, STOXX etc.

Disclosure of clinical trials in line with AstraZeneca policy requirements.Completion of best-practice review. Development and availability of best-practice toolkit.